PhaseBio Pharmaceuticals EBT

EBT of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT growth rates and interactive chart. Earnings before tax (EBT) measures a company's financial performance. Its calculation is revenue minus expenses, excluding taxes. EBT is a line item on a company's income statement. It shows company earnings with the cost of goods sold (COGS), interest, depreciation, general and administrative expenses, and other operating expenses deducted from gross sales.


Highlights and Quick Summary

  • EBT for the quarter ending September 29, 2021 was $-31.9 Million (a 17.89% increase compared to previous quarter)
  • Year-over-year quarterly EBT increased by 5.1%
  • Annual EBT for 2020 was $-98.6 Million (a 126.86% increase from previous year)
  • Annual EBT for 2019 was $-43.4 Million (a 59.46% increase from previous year)
  • Annual EBT for 2018 was $-27.2 Million (a 102.62% increase from previous year)
  • Twelve month EBT ending September 29, 2021 was $-117 Million (a 6.17% increase compared to previous quarter)
  • Twelve month trailing EBT increased by 18.44% year-over-year
Trailing EBT for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-117 Million $-110 Million $-111 Million $-98.6 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT of PhaseBio Pharmaceuticals

Most recent EBTof PHAS including historical data for past 10 years.

Interactive Chart of EBT of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EBT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-31.92 $-27.08 $-27.36
2020 $-30.38 $-25.14 $-28.14 $-14.91 $-98.57
2019 $-11.33 $-11.39 $-9.23 $-7.29 $-43.45
2018 $-4.87 $-7.9 $-6.67 $-4.4 $-27.25
2017 $-2.56 $-13.45
2016 $-9.22

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.